The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Clinical Experience With Excitatory Amino Acid Antagonist Drugs
Abstract
Background Excitotoxic damage due to excess release of neuronal glutamate is hypothesized to play a pivotal role in the pathogenesis of focal cerebral ischemia. Drugs that antagonize excitatory amino acid function are consistently neuroprotective in preclinical models of stroke, and many are now entering clinical trials. Summary Antagonists of the N-methyl-d-aspartate (NMDA) receptor are furthest advanced in clinical development for stroke. Both noncompetitive (aptiganel hydrochloride, dextrorphan) and competitive (selfotel,d-CPPene) antagonists have undergone tolerability studies in acute stroke and traumatic brain injury. These agents all cause a similar spectrum of neuropsychological symptoms, and several have important cardiovascular effects. Other modulatory sites on the NMDA receptor complex, notably the polyamine and magnesium ion sites, are also the subject of clinical trials. Glycine site antagonists are in early clinical development. Non-NMDA glutamate receptor antagonists remain in preclinical study. Neuroprotection by agents that block glutamate release in vitro may be due to sodium channel blockade in vivo, but some agents (619C89) exhibit neurological effects similar to NMDA antagonists in stroke. The therapeutic index is unknown for different drugs but may be determined by cardiovascular effects, especially hypotension, which may be detrimental after stroke. Conclusions Excitatory amino acid antagonists are in advanced development in the treatment of stroke and traumatic brain injury. A similar pattern of side effects is apparent with the majority of agents. However, cardiovascular effects may ultimately define therapeutic index for each drug.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Glycine potentiates the NMDA response in cultured mouse brain neurons
Johnson, J. W., & Ascher, P. (1987) · Nature · doi:10.1038/325529a0 · Cited by 3,139
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Excitatory Amino Acids as a Final Common Pathway for Neurologic Disorders
Epstein, F. H., Lipton, S. A., & Rosenberg, P. A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403033300907 · Cited by 2,658
A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis
Bensimon, G., Lacomblez, L., & Meininger, V. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403033300901 · Cited by 2,233
Ketamine—its pharmacology and therapeutic uses
white, P. F., Way, W. L., & Trevor, A. J. (1982) · Anesthesiology · doi:10.1097/00000542-198202000-00007 · Cited by 1,474
Kainic acid as a tool in neurobiology
McGeer, E. G., Olney, J. W., & McGeer, P. L. (1978) · Raven Press eBooks · Cited by 1,308
Pathological Changes Induced in Cerebrocortical Neurons by Phencyclidine and Related Drugs
Olney, J. W., Labruyere, J., & Price, M. T. (1989) · Science · doi:10.1126/science.2660263 · Cited by 1,237
Beal, M. F. (1992) · Annals of Neurology · doi:10.1002/ana.410310202 · Cited by 961
Study of a New Schizophrenomimetic Drug—Sernyl
LUBY, E. D. (1959) · Archives of Neurology And Psychiatry · doi:10.1001/archneurpsyc.1959.02340150095011 · Cited by 921
Cited by
Recommendations for Standards Regarding Preclinical Neuroprotective and Restorative Drug Development
(1999) · Stroke · doi:10.1161/01.str.30.12.2752 · Cited by 1,251
Adams, H. P., Adams, R. J., Brott, T., del Zoppo, G. J., Furlan, A., Goldstein, L. B., Grubb, R. L., Higashida, R., Kidwell, C., Kwiatkowski, T. G., et al. (2003) · Stroke · doi:10.1161/01.str.0000064841.47697.22 · Cited by 1,245
Signaling pathways involved in ischemic stroke: molecular mechanisms and therapeutic interventions
Qin, C., Yang, S., Chu, Y.-H., Zhang, H., Pang, X.-W., Chen, L., Zhou, L.-Q., Chen, M., Tian, D.-S., & Wang, W. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01064-1 · Cited by 939
Parsons, C. G., Danysz, W., & Quack, G. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00019-2 · Cited by 878
The Role of Excitotoxicity in Neurodegenerative Disease
Doble, A. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00042-4 · Cited by 723
Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels
Hansen, K. B., Wollmuth, L. P., Bowie, D., Furukawa, H., Menniti, F. S., Sobolevsky, A. I., Swanson, G. T., Swanger, S. A., Greger, I. H., Nakagawa, T., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000131 · Cited by 686
Oxidative Stress in Brain Ischemia
Love, S. (1999) · Brain Pathology · doi:10.1111/j.1750-3639.1999.tb00214.x · Cited by 685
Increased cortical kynurenate content in schizophrenia
Schwarcz, R., Rassoulpour, A., Wu, H.-Q., Medoff, D., Tamminga, C. A., & Roberts, R. C. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01078-2 · Cited by 590
Efficacy of High-Dose Glycine in the Treatment of Enduring Negative Symptoms of Schizophrenia
Heresco-Levy, U., Javitt, D. C., Ermilov, M., Mordel, C., Silipo, G., & Lichtenstein, M. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.1.29 · Cited by 487
Fischer, G., Mutel, V., Trube, G., Malherbe, P., Kew, J. N. C., Mohacsi, E., Heitz, M. P., & Kemp, J. A. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37138-1 · Cited by 479
Loddick, S. A., & Rothwell, N. J. (1996) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199609000-00017 · Cited by 463
Leker, R. R., & Shohami, E. (2002) · Brain Research Reviews · doi:10.1016/s0165-0173(02)00157-1 · Cited by 409
Peikert, A., Wilimzig, C., & Köhne-Volland, R. (1996) · Cephalalgia · doi:10.1046/j.1468-2982.1996.1604257.x · Cited by 364
Robinson, M. M., Mcbryant, S. J., Tsukamoto, T., Rojas, C., Ferraris, D. V., Hamilton, S. K., Hansen, J. C., & Curthoys, N. P. (2007) · Biochemical Journal · doi:10.1042/bj20070039 · Cited by 340
Targeting NMDA receptors in stroke: new hope in neuroprotection
Wu, Q. J., & Tymianski, M. (2018) · Molecular Brain · doi:10.1186/s13041-018-0357-8 · Cited by 319
Meythaler, J. M., Brunner, R. C., Johnson, A., & Novack, T. A. (2002) · Journal of Head Trauma Rehabilitation · doi:10.1097/00001199-200208000-00004 · Cited by 313
Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists
MUIR, K. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.12.002 · Cited by 312
Self-citationObrenovitch, T. P., & Urenjak, J. (1997) · Progress in Neurobiology · doi:10.1016/s0301-0082(96)00049-4 · Cited by 307
Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury
Slusher, B. S., Vornov, J. J., Thomas, A. G., Hurn, P. D., Harukuni, I., Bhardwaj, A., Traystman, R. J., Robinson, M. B., Britton, P., Lu, X.-C. M., et al. (1999) · Nature Medicine · doi:10.1038/70971 · Cited by 295
Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases
Alexi, T. (2000) · Progress in Neurobiology · doi:10.1016/s0301-0082(99)00032-5 · Cited by 295
Castillo, J., Dávalos, A., Naveiro, J., & Noya, M. (1996) · Stroke · doi:10.1161/01.str.27.6.1060 · Cited by 258
Possible involvement of group I mGluRs in neuroprotective effect of theanine
Nagasawa, K., Aoki, H., Yasuda, E., Nagai, K., Shimohama, S., & Fujimoto, S. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.05.143 · Cited by 48
(1999) · doi:10.1002/(sici)1097-4547(19990915)57:6<830::aid-jnr8>3.0.co;2-2
Metadata
- Authors
- Muir, K. W., & Lees, K. R.
- Venue
- Stroke
- Published
- 1995-03
- Volume
- 26
- Issue
- 3
- Pages
- 503-513
- ISSN
- 0039-2499 (ISSN-L)
- 1524-4628
- OpenAlex
- W2003066583
- Cited by
- 502
- References
- 88
- FWCI
- 45.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.